In fact, multifactorial hyporesponsiveness to PTH is a well-documented consequence of CKD (Evenepoel et al., 2016; Bover et al., 2021c) and a certain degree of secondary hyperparathyroidism is beneficial in CKD patients, not only because of the positive PTH phosphaturic effect but also in order to maintain a normal bone formation rate (Ketteler et al., 2022; Torregrosa et al., 2022). The gene discussed is PTH; the disease is secondary hyperparathyroidism.